We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.71%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$810M
AUM Growth
-$260M
Cap. Flow
-$189M
Cap. Flow %
-23.28%
Top 10 Hldgs %
32%
Holding
105
New
11
Increased
30
Reduced
42
Closed
19

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$17.2M
2
VEEV icon
Veeva Systems
VEEV
+$16.8M
3
BSX icon
Boston Scientific
BSX
+$15.5M
4
ABT icon
Abbott
ABT
+$12.6M
5
WAY
Waystar Holding Corp
WAY
+$9.09M

Top Sells

Rank Stock Value
1
COO icon
Cooper Companies
COO
+$22M
2
VERA icon
Vera Therapeutics
VERA
+$21.3M
3
MDT icon
Medtronic
MDT
+$19.7M
4
DHR icon
Danaher
DHR
+$17.2M
5
ALGN icon
Align Technology
ALGN
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
51
Apogee Therapeutics
APGE
$10.1B
$6.31M 0.78%
+75,000
New +$5.45M
GPCR icon
52
Structure Therapeutics
GPCR
$3.53B
$6.17M 0.76%
128,100
-19,500
-13% -$1.33M
CAH icon
53
Cardinal Health
CAH
$54.7B
$5.71M 0.7%
+27,000
New +$5.81M
EHC icon
54
Encompass Health
EHC
$11B
$5.44M 0.67%
56,263
-90,000
-62% -$9.23M
AMGN icon
55
Amgen
AMGN
$210B
$5.35M 0.66%
15,200
-20,800
-58% -$7.42M
VKTX icon
56
Viking Therapeutics
VKTX
$3.84B
$5.21M 0.64%
160,000
+77,000
+93% +$2.47M
NRIX icon
57
Nurix Therapeutics
NRIX
$2.56B
$4.86M 0.6%
313,500
-224,000
-42% -$3.71M
ALKS icon
58
Alkermes
ALKS
$8.33B
$4.71M 0.58%
133,250
– –
CRL icon
59
Charles River Laboratories
CRL
$11.3B
$4.49M 0.55%
26,000
+4,000
+18% +$742K
MLTX icon
60
MoonLake Immunotherapeutics
MLTX
$1.53B
$4.46M 0.55%
239,500
-124,500
-34% -$2.06M
KRYS icon
61
Krystal Biotech
KRYS
$9.61B
$4.31M 0.53%
16,675
-8,325
-33% -$2.22M
DOCS icon
62
Doximity
DOCS
$3.99B
$4.28M 0.53%
183,808
-188,942
-51% -$5.89M
NKTR icon
63
Nektar Therapeutics
NKTR
$2.46B
$4.25M 0.52%
+59,000
New +$3.36M
DNLI icon
64
Denali Therapeutics
DNLI
$3.84B
$3.82M 0.47%
199,000
+99,000
+99% +$1.97M
STVN icon
65
Stevanato
STVN
$5.36B
$3.78M 0.47%
274,676
+127,651
+87% +$2.11M
RLAY icon
66
Relay Therapeutics
RLAY
$4.26B
$3.58M 0.44%
360,000
-100,000
-22% -$895K
COO icon
67
Cooper Companies
COO
$14.6B
$3.58M 0.44%
50,000
-277,500
-85% -$22M
SION
68
Sionna Therapeutics
SION
$2.25B
$3.51M 0.43%
+87,500
New +$3.34M
ASND icon
69
Ascendis Pharma A/S
ASND
$16B
$3.43M 0.42%
15,000
– –
DHR icon
70
Danaher
DHR
$137B
$3.42M 0.42%
18,052
-81,000
-82% -$17.2M
PODD icon
71
Insulet
PODD
$11.6B
$2.94M 0.36%
14,000
-47,000
-77% -$11.8M
A icon
72
Agilent Technologies
A
$39.3B
$2.85M 0.35%
25,000
+5,000
+25% +$634K
STOK icon
73
Stoke Therapeutics
STOK
$1.97B
$2.7M 0.33%
83,000
-133,000
-62% -$4.36M
ESPR
74
DELISTED
Esperion Therapeutics
ESPR
$2.7M 0.33%
+985,000
New +$3.12M
IMCR icon
75
Immunocore
IMCR
$1.69B
$2.58M 0.32%
85,724
-67,554
-44% -$2.19M
1 2
3
4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rhenman & Partners Asset Management held 105 positions worth $810M, down 24% from $1.07B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $189M in Q1 2026, closing 19 positions and reducing 42 holdings. Its most notable exit was Vera Therapeutics, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Stryker worth $15.7M.

  • Rhenman & Partners Asset Management's largest Q1 2026 buy was Stryker: 47,800 shares worth $15.7M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q1 2026, an estimated $15.5M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2026 reduction was Cooper Companies, cutting an estimated $22M.
  • Rhenman & Partners Asset Management fully exited Vera Therapeutics in Q1 2026, selling an estimated $21.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $810M portfolio in Q1 2026.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 19 in Q1 2026.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $810M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.